Copenhagen Pharma Consulting ApS: Financial statements 2023
CVR: 41537388
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Copenhagen Pharma Consulting ApS (CVR 41537388) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 2,931,273 and a net result of DKK 335,687 compared with DKK -37,796 the year before. That is an increase of 124.7% compared with the year before. Equity in the 2023 report amounted to DKK 1,241,847. The solvency ratio was 52.8%. The company had 2 employees in the financial year.
- Gross Profit
- DKK 2,931,273
- Profit/Loss
- DKK 335,687
- Equity
- DKK 1,241,847
- Total Assets
- DKK 2,351,671
- Employees
- 2
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Copenhagen Pharma Consulting ApS has published its annual report for 2022. Gross profit came to DKK 1,304,771, and the net result was DKK -37,796.
About Copenhagen Pharma Consulting ApS
Copenhagen Pharma Consulting ApS is a Danish company of the type Anpartsselskab based in Vanløse, founded in 2020. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The management consists of Lars Holten-Andersen. The company is owned by Obi1 Holding ApS. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK 3,364,006 and a net result of DKK 419,568 compared with DKK 558,252 the year before. Equity in the 2025 report amounted to DKK 601,867.
